Bacterial diseases caused by species such as Vibrio , Lactococcus , and Streptococcus lead to major financial losses in fish farming. These risks are often increased by rising water temperatures and stressful rearing conditions. Many pathogens cause subclinical infections without showing clear signs, allowing the disease to spread unnoticed while slowing growth and raising production costs. Organic acids deliver bacterial inhibitory properties and are often used to support the health management strategy and bacterial control.
This research evaluated an aqua -specific blend of organic acids (Bacti-Nil Aqua (BNA), Adisseo) to reduce the severity of bacterial infections through a multi-stage approach, including laboratory tests, controlled challenges, and real farm condition trial . Firstly, M inimum i nhibitory c oncentration (MIC) tests identified the smallest concentration of BNA needed to inhibit field isolates of Vibrio , Lactococcus , Streptococcus , and Carnobacterium from Asia, Europe, and South America. Secondly, i n a controlled in vivo test, Nile tilapia with an initial body weight of 20 g were first fed a diet supplemented with a preventive dose of BNA (0.2%) for 30 days, followed by a corrective dose (0.5%) during a 14-day co-infection with Aeromonas and Streptococcus . Finally, a commercial farm trial in Thailand evaluated growth performance and profitability in tilapia with an average initial body weight of 56.5 g over a 12-week culture period, reaching an average final weight of 540 g.
The MIC results showed that BNA effectively limited bacterial growth at concentrations of 1 to 5 m g/L. In the controlled infections challenge, BNA reduced final mortality by 22%. The additive successfully delayed the time to 50% mortality (LT50) by 34% and significantly reduced the bacterial load in the head kidney of challenged fish. The farm trial showed that BNA increased biomass gain by 5% and reduced the f eed c onversion rate (FCR) by 3%, resulting in a return on investment (ROI) of 3.5.
In conclusion, the dietary use of BNA at 0.2-0.5% showed potential as an effective health management strategy for reducing the severity of bacterial infections and ensured better growth and profitability.